Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 3/20 | 0.36 |
| ▸ | ITGA4 | P13612 | 3/20 | 0.36 |
| ▸ | TGFBR1 | P36897 | 3/20 | 0.35 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.33 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6009583 | 1.00 | ITGB1 (0.36) | ITGB1ITGA4TGFBR1OR51E2SLC22A6 | |
| SCHEMBL6009884 | 0.90 | SLC1A1 (0.33) | ITGB1ITGA4TGFBR1 | |
| SCHEMBL6009869 | 0.90 | SLC1A1 (0.33) | ITGB1ITGA4TGFBR1 | |
| SCHEMBL5712806 | 0.84 | TGFBR1 (0.42) | TGFBR1OR51E2SLC22A6 | |
| SCHEMBL5712807 | 0.84 | TGFBR1 (0.42) | TGFBR1OR51E2SLC22A6 | |
| SCHEMBL6010243 | 0.79 | LMNA (0.46) | — | |
| SCHEMBL6010246 | 0.79 | LMNA (0.46) | — | |
| SCHEMBL321603 | 0.78 | KDM4E (0.44) | TGFBR1OR51E2SLC22A6 | |
| SCHEMBL6009823 | 0.78 | SLC22A6 (0.46) | TGFBR1OR51E2SLC22A6 | |
| SCHEMBL6009828 | 0.78 | SLC22A6 (0.46) | TGFBR1OR51E2SLC22A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060018864-A1 | Cosmetic preparation containing glycerylamino acid derivative | SEIWA KASEI COMPANY, LIMITED (JP) | 2006-01-26 | — | — | US | disclosed |
| EP-1584320-A1 | COSMETIC PREPARATION CONTAINING GLYCERYLAMINO ACID DERIVATIVE | Seiwa Kasei Company, Limited (JP) | 2005-10-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060018864-A1 | Cosmetic preparation containing glycerylamino acid derivative | GLA, GPKOW, CUTA | ITGB1 2586/4885ITGA4 3698/4885TGFBR1 4512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.